SARS-CoV-2-specific ELISA development
Name
Roy J Immunol Meth 2020.pdf
Description
Accepted version
Size
1.49 MB
Format
Adobe PDF
Checksum (MD5)
12be7365e7304c6fa8b1785461f66bf1
Author(s)
Roy, Vicky
Fischinger, Stephanie
Atyeo, Caroline
Slein, Matthew
Loos, Carolin
Balazs, Alejandro
Luedemann, Corinne
Astudillo, Michael Gerino
Yang, Diane
Wesemann, Duane R.
Date Issued
September 2020
Journal
Journal of Immunological Methods
Publisher
Elsevier BV
Citation
Roy, Vicky et al. "SARS-CoV-2-specific ELISA development." Journal of Immunological Methods 484-485 (September 2020): 112832.
Version
Author's final manuscript
Abstract
Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jim.2020.112832
